Allarity Therapeutics (NASDAQ:ALLR) Posts Earnings Results

Allarity Therapeutics (NASDAQ:ALLR) announced its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04, Zacks reports.

Allarity Therapeutics Stock Down 0.8%

ALLR stock traded down $0.01 during trading on Friday, hitting $1.18. 199,149 shares of the company traded hands, compared to its average volume of 246,352. Allarity Therapeutics has a 1 year low of $0.61 and a 1 year high of $2.35. The stock’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.21.

Institutional Trading of Allarity Therapeutics

Several large investors have recently made changes to their positions in ALLR. Jane Street Group LLC acquired a new position in shares of Allarity Therapeutics during the second quarter worth $27,000. Geode Capital Management LLC raised its stake in Allarity Therapeutics by 49.3% during the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares in the last quarter. XTX Topco Ltd acquired a new position in Allarity Therapeutics in the second quarter valued at $51,000. Finally, Private Advisor Group LLC purchased a new stake in shares of Allarity Therapeutics in the 3rd quarter valued at about $441,000. 11.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Ascendiant Capital Markets upped their target price on shares of Allarity Therapeutics from $9.00 to $9.25 and gave the company a “buy” rating in a research report on Friday, September 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Allarity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.